PF-Atlas › Clinical Trials › NCT03525548

A Study of VX-445 Combination Therapy in CF Subjects Homozygous for F508del

VX-445/TEZ/IVA · Phase 3

Registry ID
NCT03525548
Phase
Phase 3
Status
Completed
Drug / intervention
VX-445/TEZ/IVA
Sponsor
Vertex Pharmaceuticals Incorporated
Start
2018-08-03
Enrollment
113
Locations
44

About this trial

This study will evaluate the efficacy of VX-445 in triple combination (TC) with tezacaftor (TEZ) and ivacaftor (IVA) in subjects with cystic fibrosis (CF) who are homozygous for the F508del mutation (F/F)

View NCT03525548 on ClinicalTrials.gov →

Explore related

All VX-445/TEZ/IVA trialsAll IPF trials
Medical disclaimer. This page summarizes public trial data for NCT03525548 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.